Table 2.
Clinical status of the patients at the time of CAR-T-cell treatment.
| Remission Status | Number (%) |
|---|---|
| CR | 2 (6%) |
| PR | 9 (25%) |
| SD | 8 (22%) |
| PD | 17 (47%) |
| Bridging therapy given: Yes | 17 (47%) |
| Radiotherapy | 4 (11%) |
| Pharmacotherapy | 17 (47%) |
| MATRIx | 1 (3%) |
| R-GEMOX | 2 (6%) |
| Ibrutinib | 4 (11%) |
| Gemcitabine | 1 (3%) |
| Bendamustine | 6 (17%) |
| Polatuzumab vedotin | 4 (11%) |
| Rituximab | 9 (25%) |
| CAR-T-cell therapy type | |
| Kymriah® (Novartis) | 26 (72%) |
| Yescarta® (Gilead) | 10 (28%) |
| Lymphodepleting chemotherapy | |
| Fludarabine, Cyclophosphamide | 36 (100%) |
CAR-T: chimeric antigen receptor T cell; CR: complete remission; PR: partial remission; SD: stable disease; PD: progressive disease; MATRIx: methotrexate, cytarabine, thiotepa, and rituximab; R-GEMOX: gemcitabine, oxaliplatin, and rituximab.